Navigation Links
Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. ("Fidia") announced today that it has assumed responsibility for distributing and promoting the osteoarthritis (OA) treatment, Hyalgan (sodium hyaluronate), in the United States through its wholly-owned subsidiary, Fidia Pharma USA Inc. ("Fidia USA"). Fidia USA has engaged Interpace BioPharma, LLC. ("Interpace") to provide commercialization services to support Hyalgan.

Hyalgan was introduced in Italy in 1987. In 1997, Hyalgan became the first viscosupplementation product approved for marketing by the U.S. Food and Drug Administration.  More than 38 million doses of Hyalgan have been administered worldwide since its introduction.(1) Hyalgan is indicated to relieve pain associated with osteoarthritis (OA) of the knee when simple analgesics like acetaminophen have failed.

"We are pleased to continue providing a treatment that has helped millions of patients worldwide who have suffered the debilitating effects of osteoarthritis," said Antonio Germani, CEO of Fidia Farmaceutici S.p.A.  "Hyalgan has demonstrated its safety and efficacy in more than 90 clinical trials involving more than 13,000 patients.  Our commitment is to provide our customers and patients the quality service they deserve, including reimbursement and patient assistance as well as patient education materials. Our goal is to see to it that Hyalgan remains a sustainable treatment of choice for patients with knee pain associated with OA," said Germani.

About Osteoarthritis (OA)

According to the Arthritis Foundation, 27 million Americans suffer from OA, which is common in all races and backgrounds.  The condition usually appears after the age of 45 years. Men under age 55 years are more likely to have osteoarthritis than women in the same age range.  After 55 years, women are more commonly affected.  OA is a chronic condition characterized by the breakdown of the joint cartilage and synovial fluid, which acts as both as a lubricant and shock absorber for the knee joint.  The breakdown of the cartilage and synovial fluid causes the bones to rub against each other, causing stiffness, pain and loss of movement in the joint. While there is no cure for OA, current disease management focuses on controlling joint pain and stiffness.  

About Hyalgan

Hyalgan is based on natural hyaluronic acid which is structurally and chemically similar to hyaluronic acid that is present in the knees of healthy individuals.  Hyaluronic acid is a vital natural component of the cartilage and synovial fluid of the knee joint.

"For many years, Hyalgan has served as an important therapeutic option for sufferers of osteoarthritis," said Dr. Frank Kane of Fidia Pharma Inc.  "Its long-established safety and efficacy record has demonstrated its usefulness in relieving the pain of osteoarthritis in patients who do not get relief from simple analgesics, such as acetaminophen, or are unable to tolerate the side effects of non-steroidal anti-inflammatory agents," continued Kane.

The recommended treatment cycle for Hyalgan is five intra-articular injections given once a week for five weeks, although many patients receive significant pain relief after a three-injection regimen consisting of one injection per week for three weeks.  Hyalgan will relieve pain in a many patients for up to six months.  Hyalgan is only approved to relieve knee pain. The FDA has not evaluated Hylagan's safety and efficacy in other joints.  Full prescribing information and important safety information for Hyalgan can be found at http://www.hyalgan.com.

About Fidia Farmaceutici S.p.A

Headquartered in Abano Terme, Northeast Italy, Fidia Farmaceutici S.p.A., has over 50 years of successful R&D and industry experience with biologically active molecules.  As a model for international success, Fidia has focused its core business activities on hyaluronic acid and glycosaminoglycan derivates, developing and providing a wide range of products for various specialties. Fidia holds more than 960 patents on hyaluronic acid and its applications and its products are currently available in over 70 countries worldwide.  Fidia's most important proprietary platform technology at a worldwide level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories such a Joint Care, Advanced Wound Care, and Aesthetic Dermatology.

Helping people stay healthy is Fidia's corporate commitment.  For more information, visit www.fidiapharma.com.

About Interpace BioPharma, LLC.

Located in Parsippany, NJ, Interpace is a wholly owned subsidiary of PDI, Inc., a leading company that provides a wide range of commercialization services to the life science industry. Interpace provides marketing, sales, and product distribution support to manufacturers of pharmaceutical and biological drugs, medical devices and clinical diagnostics.  

(1) Data on File, Fidia Farmaceutici S.p.A.


'/>"/>
SOURCE Fidia Farmaceutici S.p.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.
2. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
3. VWR International, LLC Acquires INTERNATIONAL P.B.I. S.p.A.
4. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
5. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
6. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
7. Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S.
8. Patient Advocacy Group Distributes Wallet Cards to Help Protect Patients from Medication Switching
9. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
10. Draeger Announces Partnership With L. N. Curtis & sons to Distribute Emergency Responder Equipment
11. As Cholera Outbreak Spreads, World Vision Deploys Teams to Distribute Emergency Health Supplies, Focus on Preventative Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):